Gail Matthews of the Kirby Institute spoke of HCV elimination from a clinician’s perspective. Currently only 9 countries are on track to meet targets set out by WHO, with Malaysia and Georgia the only two low income countries. Throughout the conference we have heard the barrier of costs of accessing medications can have on effective roll out of health service programs. Whilst this is of course true it is not the complete solution in achieving HCV elimination. Dr Matthews illustrated that even in Australia where we are successfully meeting WHO targets and have universal access to HCV medications, DAA uptake has significantly declined.